-
April 15, 2013
The venture capital arm of Boehringer Ingelheim has made an equity investment into France's Eyevensys, which has developed a new process for non-viral gene therapy using electrotransfer that produces proteins for the treatment of ocular disease
Full story
-
November 04, 2012
European regulators have given the green light to UniQure's Glybera, which makes it the first gene therapy to be approved in the western world
Full story
-
July 23, 2012
Much excitement has greeted the news that European regulators have finally recommended approval of Glybera, which should make it the first gene therapy to be approved in the western world
Full story
-
March 20, 2012
A £3.1 million award from the Medical Research Council (MRC) and the National Institute for Health Research (NIHR) will enable a UK consortium to move ahead with efficacy testing of its inhaled gene therapy for cystic fibrosis.
Full story
-
December 12, 2011
A small study which shows that symptoms improved significantly in adults with the bleeding disorder haemophilia B following a single treatment with gene therapy has caused a stir among the scientific community.
Full story
-
October 31, 2011
Oxford BioMedica of the UK has linked up with the USA's renowned Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma
Full story
-
August 08, 2011
GlaxoSmithKline's efforts to tackle a rare and often deadly immune deficiency are making progress following a deal signed with Italy's MolMed
Full story
-
August 01, 2011
The market for regenerative medicine is set to explode over the next decade, according to a new report
Full story
-
June 23, 2011
UK drugmaker Oxford BioMedica's stock was given a nudge this week as shareholders welcomed encouraging results from a Phase I study of its gene-based eye therapy RetinoStat.
Full story
-
December 23, 2010
Shares in Oxford BioMedica were on the rise yesterday after it announced encouraging data from a Phase I/II trials of ProSavin, backing earlier findings indicating that the drug is safe and effective in patients with Parkinson's disease.
Full story